Artiva Biotherapeutics, Inc. 4

Director Daniel G. Baker received an option award for 16,250 shares of Artiva Biotherapeutics, Inc. common stock at an exercise price of $10.42 per share.

On September 10, 2026, director Daniel G. Baker received a stock option award from Artiva Biotherapeutics, Inc. covering 16,250 shares of common stock at an exercise price of $10.42 per share. This director stock option (right to buy) is a compensatory, non-open-market grant that will vest in full on the earlier of September 10, 2027, or the date of the issuer’s 2027 annual stockholder meeting, and it increases his derivative-based exposure to the company without any immediate cash outlay. Following the grant, Baker holds 16,250 options corresponding to 16,250 shares of common stock, with an intrinsic exposure value (based on the exercise price) of approximately $169,325.

Filing Facts

CIK

1817241

Ticker

ARTV

Form

4

Source Type

fda

Accession

0001193125-26-390527

Alert Tier

5